Clinical Trials Logo

Heart Diseases clinical trials

View clinical trials related to Heart Diseases.

Filter by:

NCT ID: NCT04290481 Completed - High Altitude Clinical Trials

Oxygen Saturation and Perfusion Index ın Neonates at High Altitude

Start date: June 1, 2018
Phase:
Study type: Observational

Congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. This figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. Most of these defects do not need treatment or treatment is needed after infancy. Other defects are severe and usually require early treatment in the neonatal period. Critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. Critical congenital heart disease is estimated to be ~3 in 1000 live births. It is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. Even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed. Screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease. The American Academy of Pediatrics, the American Cardiology Foundation and the American Heart Association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia. The reference values of peripheral perfusion (PPI) index has been established for normal newborns between 1 and 120 h of age. Lower PPI values than 0.70 may indicate illness. Including cut-off values for PPI in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation. We aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.

NCT ID: NCT04288596 Not yet recruiting - Clinical trials for Patent Foramen Ovale

Canadian Adult Congenital Heart Disease Intervention Registry

C-ACHDiR
Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

The ACHDi Registry study will create a foundational database for adult congenital heart disease interventions. This Pan-Canadian Registry will collect clinical and patient-reported information that will enable the evaluation of care processes and outcomes in five most common ACHDi interventions by enabling prospective and retrospective registry-based studies to answer important clinical practice and policy-relevant questions.

NCT ID: NCT04284995 Completed - Clinical trials for Myocardial Infarction

A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction

CEL-02
Start date: June 2, 2020
Phase: Phase 2
Study type: Interventional

RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study is designed to extend the findings in CEL-01 to patients with ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization laboratory with planned coronary angioplasty.

NCT ID: NCT04282499 Completed - Hypertension Clinical Trials

Effects of Exercise Training on Blood Pressure Variability

VARIABILITA'
Start date: January 4, 2019
Phase: N/A
Study type: Interventional

A Randomized clinical evaluation of the effects of 2 exercise training modalities on blood pressure variability. Recruited subjects will be randomized in two interventional arms: 1) aerobic exercise; 2) combined exercise (aerobic+resistance training).

NCT ID: NCT04278625 Completed - Clinical trials for Congenital Heart Disease

Pharmacokinetics of Acetaminophen in Pediatric Patients With Congenital Heart Disease

Start date: March 23, 2021
Phase:
Study type: Observational

This is a prospective study of pediatric patients with congenital heart disease, in which acetaminophen serum concentrations will be measured following a single intraoperative intravenous dose of acetaminophen. These levels will be used to develop a pharmacokinetic model. Serum concentrations will be compared between two groups of patients: (1) cyanotic patients presenting for the Fontan completion operation and (2) patients with acyanotic congenital heart disease presenting for repair via median sternotomy.

NCT ID: NCT04271358 Active, not recruiting - Clinical trials for Congenital Heart Disease

Peer Coaching Intervention in Young Adults With Congenital Heart Disease

CHASM in ACHD
Start date: October 8, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate a peer coaching intervention in young adults with congenital heart disease.

NCT ID: NCT04271098 Completed - Surgery Clinical Trials

The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries

Start date: January 1, 2012
Phase:
Study type: Observational [Patient Registry]

In a prospective observational study during the six-month duration, coronary artery bypass graft surgery (CABG) and valve repair surgery (mitral, mitral, and aortic valve and/or tricuspid valve) patients were investigated for hepatic dysfunction. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. Our goal was to determine the risk factors associated with hepatic dysfunction in patients undergoing open-heart surgery with cardiopulmonary bypass. The collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days 1, 3 and 7. Possible preoperative, intraoperative, and postoperative risk factors were investigated. Logistic regression analysis was done to identify the risk factors for postoperative hyperbilirubinemia.

NCT ID: NCT04270279 Not yet recruiting - Clinical trials for Coronary Heart Disease

Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris

Start date: December 2020
Phase: Phase 4
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in Chinese population with stable angina pectoris. The purpose is to determine the efficacy and safety of Xueshuanxinmaining tablet in the treatment of stable angina pectoris.

NCT ID: NCT04270071 Not yet recruiting - Clinical trials for Coronary Heart Disease

Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris

Start date: December 2020
Phase: Phase 4
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in Chinese population with stable angina pectoris. The purpose is to determine the efficacy and safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.

NCT ID: NCT04265443 Completed - Clinical trials for Ischemic Heart Disease

Prognostic Perspective of Invasive Hyperemic and Non-Hyperemic Physiologic Indices Measured After Percutaneous Coronary Intervention

PERSPECTIVEPCI
Start date: May 13, 2013
Phase:
Study type: Observational

Coronary physiologic assessments by the pressure-derived fractional flow reserve (FFR) have become standard methods for identifying hemodynamic deprivation in coronary arterial stenosis for evidence-based percutaneous coronary intervention (PCI). Invasive physiologic indices-guidance enables on-site real time assessment for functional significance of epicardial coronary stenosis and the use of those indices has shown to be effective to guide treatment decision. Several studies further support the role of post-PCI FFR measurement as a functional marker of residual disease after PCI and prognostic indicator of patients. Although optimal cut-off values of post-PCI FFR varied across studies, an inverse relationship between post-PCI FFR and the risk of future clinical events have been reported consistently. Recently, non-hyperemic pressure ratios (NHPRs) have been introduced in clinical practice. Although there are several different NHPRs, previous studies consistently indicated that those NHPRs shares similar diagnostic performance and prognostic implications. Nevertheless, few reports were available for clinical relevance of NHPRs in evaluation of post-PCI status. In this context, we will evaluate the physiologic characteristics and prognostic implication of post-PCI NHPRs and compare with those of post-PCI FFR in patients who underwent angiographically successful PCI with 2nd generation drug-eluting stent implantation (DES).